Paper42876375PubMed
Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab.
Kaneko S and 10 others. Thorac Cancer, 2026.
Cite this record
ConductScience Library. Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab. Papers, record 42876375. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42876375
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinicopathological Features of DLL3 Expression and T-Cell Infiltration in LCNEC: Insights From Pathology and Clinical Response to Tarlatamab.
- Journal
- Thorac Cancer
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-17
Source PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Membrane Proteins | Major topic |
| Intracellular Signaling Peptides and Proteins | Major topic |
| Lymphocytes, Tumor-Infiltrating | Major topic |
| Carcinoma, Neuroendocrine | Major topic |
| Lung Neoplasms | Major topic |
| Carcinoma, Large Cell | Major topic |
| Humans | |
| Female | |
| Male | |
| Aged | |
| Prognosis | |
| Retrospective Studies | |
| Aged, 80 and over | |
| Middle Aged | |
| CD8-Positive T-Lymphocytes | |
| Antibodies, Bispecific |
Source PubMed
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29378266 | Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. | J Thorac Oncol | 2018 | https://conductscience.org/library/papers/29378266 | PubMed |
| 2 | 35983951 | DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. | Oncologist | 2022 | https://conductscience.org/library/papers/35983951 | PubMed |
| 3 | 31678831 | DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile. | Lung Cancer | 2019 | https://conductscience.org/library/papers/31678831 | PubMed |
| 4 | 39309421 | Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report. | JTO Clin Res Rep | 2024 | https://conductscience.org/library/papers/39309421 | PubMed |
| 5 | 31903172 | Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis. | Oncotarget | 2019 | https://conductscience.org/library/papers/31903172 | PubMed |
| 6 | 32691982 | DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC. | Thorac Cancer | 2020 | https://conductscience.org/library/papers/32691982 | PubMed |
| 7 | 23208313 | Investigation of the freely available easy-to-use software 'EZR' for medical statistics. | Bone Marrow Transplant | 2013 | https://conductscience.org/library/papers/23208313 | PubMed |
| 8 | 37930513 | Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer. | Target Oncol | 2023 | https://conductscience.org/library/papers/37930513 | PubMed |
| 9 | 33859752 | Turning cold tumors into hot tumors by improving T-cell infiltration. | Theranostics | 2021 | https://conductscience.org/library/papers/33859752 | PubMed |
| 10 | 40284515 | Targeting DLL3: Innovative Strategies for Tumor Treatment. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40284515 | PubMed |
| 11 | 34808341 | The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. | J Thorac Oncol | 2022 | https://conductscience.org/library/papers/34808341 | PubMed |
| 12 | 39372398 | Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis. | Front Immunol | 2024 | https://conductscience.org/library/papers/39372398 | PubMed |
| 13 | 40440602 | Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies. | Am Soc Clin Oncol Educ Book | 2025 | https://conductscience.org/library/papers/40440602 | PubMed |
| 14 | 40706016 | Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/40706016 | PubMed |
| 15 | 33482121 | Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. | Cancer Cell | 2021 | https://conductscience.org/library/papers/33482121 | PubMed |
| 16 | 37114477 | Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis. | Expert Rev Anticancer Ther | 2023 | https://conductscience.org/library/papers/37114477 | PubMed |
| 17 | 30885341 | Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). | Lung Cancer | 2019 | https://conductscience.org/library/papers/30885341 | PubMed |
| 18 | 32745892 | International real-world study of DLL3 expression in patients with small cell lung cancer. | Lung Cancer | 2020 | https://conductscience.org/library/papers/32745892 | PubMed |
| 19 | 31087628 | The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. | Cancer Med | 2019 | https://conductscience.org/library/papers/31087628 | PubMed |
| 20 | 36689692 | Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36689692 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42876375
GET https://conductscience.org/api/papers/v1/42876375/references?page=2